The increased tumor infiltration and cytotoxicity of CD8+ T cells seen under EZM2302 treatment prompted us to examine immune responses in breast cancer cell lines, PDXs, and 4T1.2 tumors. The gene discussed is CD8A; the disease is breast carcinoma.